Journal
NEUROCHEMISTRY INTERNATIONAL
Volume 149, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuint.2021.105136
Keywords
Antioxidant; Glioblastoma; ROS; Temozolomide
Categories
Funding
- Spanish Ministry of Science and Technology [RTI2018-096866-B-I00]
- Ministerio de Ciencia, Innovacion y Universidades [FPU17/04084]
Ask authors/readers for more resources
Glioblastoma is a highly challenging and devastating cancer with low survival rates, despite the current standard treatment consisting of surgery, radiation therapy, and chemotherapy. Patients often develop resistance to chemotherapy drugs, leading to tumor progression and recurrence.
Glioblastoma remains one of the most challenging and devastating cancers, with only a very small proportion of patients achieving 5-year survival. The current standard of care consists of surgery, followed by radiation therapy with concurrent and maintenance chemotherapy with the alkylating agent temozolomide. To date, this drug is the only one that provides a significant survival benefit, albeit modest, as patients end up acquiring resistance to this drug. As a result, tumor progression and recurrence inevitably occur, leading to death. Several factors have been proposed to explain this resistance, including an upregulated antioxidant system to keep the elevated intracellular ROS levels, a hallmark of cancer cells, under control. In this review, we discuss the mechanisms of chemoresistance -including the important role of glioblastoma stem cells-with emphasis on antioxidant defenses and how agents that impair redox balance (i.e.: sulfasalazine, erastin, CB-839, withaferin, resveratrol, curcumin, chloroquine, and hydroxychloroquine) might be advantageous in combined therapies against this type of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available